Vor Biopharma Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | Description | Form | File No. | Exhibit Number | Filing Date | Filed Herewith |
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant | 8-K | 001-39979 | 3.1 | February 9, 2021 | |
| 3.2 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant | 8-K | 001-39979 | 3.1 | May 23, 2025 | |
| 3.3 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant | 8-K | 001-39979 | 3.1 | September 17, 2025 | |
| 3.4 | Amended and Restated Bylaws of the Registrant | 8-K | 001-39979 | 3.2 | February 9, 2021 | |
| 4.1 | Form of Common Stock Certificate of the Registrant | S-3 | 333-290490 | 4.5 | September 24, 2025 | |
| 4.2 | Amended and Restated Investors’ Rights Agreement, by and among the Registrant and certain of its stockholders, dated June 30, 2020 | S-1/A | 333-252175 | 4.2 | February 1, 2021 | |
| 10.1+ | Employment Agreement, dated as of July 9, 2025, by and between the Registrant and Sandesh Mahatme | 8-K | 001-39979 | 10.1 | July 10, 2025 | |
| 10.2+ | Employment Agreement, dated as of July 17, 2025, by and between the Registrant and Qing Zuraw | 8-K | 001-39979 | 10.1 | July 22, 2025 | |
| 10.3* | License Agreement, dated as of June 25, 2025, by and between RemeGen Co, Ltd. and the Registrant | 10-Q | 001-39979 | 10.9 | August 12, 2025 | |
| 10.4^ | Lease Agreement, dated August 5, 2025, by and between the Company and 500 Boylston & 222 Berkeley Owner (DE) LLC | 10-Q | 001-39979 | 10.10 | August 12, 2025 | |
| 10.5+ | Vor Biopharma Inc. Amended and Restated 2021 Equity Incentive Plan | 8-K | 001-39979 | 10.1 | August 27, 2025 | |
| 10.6+ | Amendment to Employment Agreement, dated November 2, 2025, by and between the Registrant and Qing Zuraw | X | ||||
| 31.1 | Certification of Principal Executive Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 31.2 | Certification of Principal Financial Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 32.1† | Certification of Principal Executive and Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 101.INS | Inline XBRL Instance Document | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X |
| 104 | The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in Inline XBRL. |
- Indicates management contract or compensatory plan.
- Portions of the exhibit have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential.
^ Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant will furnish a supplemental copy of any omitted schedule or similar attachment to the SEC upon request.
† The certifications furnished in Exhibit 32.1 hereto are deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.